Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir

Background and Aim Loss of hepatitis B surface antigen (HBsAg) is an important goal in the treatment of chronic hepatitis B. We investigated whether switching from long‐term entecavir (ETV) administration to tenofovir (TFV) (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF]) could c...

Full description

Bibliographic Details
Main Authors: Nobuharu Tamaki, Masayuki Kurosaki, Sakura Kirino, Koji Yamashita, Leona Osawa, Shuhei Sekiguchi, Yuka Hayakawa, Wan Wang, Mao Okada, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Shun Kaneko, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Nobuyuki Enomoto, Namiki Izumi
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:JGH Open
Subjects:
chronic hepatitis B
entecavir
hepatitis B surface antigen
tenofovir
Online Access:https://doi.org/10.1002/jgh3.12273

Internet

https://doi.org/10.1002/jgh3.12273

Similar Items